The adMare portfolio

Pharma Inventor is a Canadian contract research organization (CRO) specializing in chemistry R&D, analytical services, and biological sciences.

Based in Vancouver, the company supports researchers across the pharmaceutical, biotechnology, and agrochemical industries, as well as academic institutions, in addressing complex scientific challenges. Its internationally trained team of scientists provides tailored research solutions, ranging from custom chemical synthesis and analytical method development to DMPK services and biological testing.

By combining scientific expertise, inventive chemistry, and close collaboration with its clients, Pharma Inventor delivers customized support to meet the specific needs of research projects at various stages of drug discovery and development.

Reverb develops innovative medicines that intelligently reshape the immune system to fight cancer and other life-threatening conditions more effectively.

At the core of its approach is Amplify•R™, a proprietary platform designed to harness the potential of the natural immune system by amplifying and redirecting the body’s own cytokine signals. Through the development of bispecific antibodies, this technology aims to enhance the activity of immune cells, including T cells and natural killer (NK) cells, to strengthen the body’s anti-tumor response.

Unlike approaches that rely on the administration of exogenous cytokines, Amplify•R™ leverages the body’s natural immune signaling mechanisms to achieve clinical benefits while aiming to reduce the risks of systemic toxicity and immunogenicity. By combining deep immunological expertise with computational modeling and AI-guided optimization, Reverb seeks to develop more targeted, effective, and better-tolerated treatments for patients.

Resilience Biosciences is a clinical-stage biopharmaceutical company located in the AdMare Innovation Centre on the UBC campus in Vancouver, Canada.

Founded by internationally-renowned scientists and medical professionals, RBI builds on two decades of translational neuroscience research at the University of British Columbia and long-standing international clinical partnerships.

Resilience Biosciences is committed to developing non-opioid, evidence-based, herbal and small-molecule therapeutics to help address global public health challenges related to opioid withdrawal, associated pain, and cognitive impairment.

Kore Biomedical Inc. is a clean-technology startup based in Burnaby, British Columbia, developing an innovative solution to reduce the environmental impact of anesthetic gases used in operating rooms. Its technology chemically destroys over 95% of these gases at the source, converting them into inert byproducts rather than storing or recycling them. By integrating seamlessly with existing hospital scavenging systems, Kore Biomedical aims to combine clinical performance, anesthetic choice, and reduced greenhouse gas emissions.

Discovery Genomics uses DNA sequencing and microbiology to help mineral exploration and mining companies find mineral deposits faster and more accurately

Founded by CEO Martine Rothblatt, United Therapeutics is transforming the treatment of rare diseases and pioneering breakthrough technologies to expand the supply of transplantable organs.

Bold in its ambitions and unconventional in its approach, the company turns scientific breakthroughs into real-world solutions. As a public benefit corporation, we are committed to serving patients, upholding the highest standards of integrity, creating long-term shareholder value, and operating sustainably.

Conexeu Sciences is commercializing a patented, collagen-based extracellular matrix scaffold, developed from IP originally developed at the University of British Columbia. Designed to support the way the body naturally repairs and restores tissue, CXU offers broad potential across five global markets including wound care, medical aesthetics, dental, orthopedic, and 3D printing applications. One Formula. One Platform.

Abdera is leveraging its proprietary ROVEr™ platform to engineer and develop new precision radiotherapeutics with tunable PK properties to maximize therapeutic effect while mitigating systemic toxicities in order to treat a broad range of solid tumors.

26 Therapeutics Inc. is a Montréal-based life sciences company developing first-in-class therapies for dry eye disease and meibomian gland disorders, high-prevalence conditions that remain poorly addressed by today’s treatments.

Bright Angel Therapeutics (BAT) is a pre-clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of drug-resistant and life-threatening fungal infections.

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumor-specific antigens, which are known as CryptigenTM TSAs, that are broadly shared across multiple patients with the same tumor type. 

Evolved Therapeutics is focused on establishing innovative antibody discovery platforms to enable the discovery of first- and best-in-class therapeutics. 

Find Therapeutics designs ground-breaking therapies through precision-targeting of membrane receptors to bring hope to people living with autoimmune diseases. 

Immugenia is an early stage immuno-oncology company developing a novel approach to CAR therapy by engineering hematopoietic stem cells to treat cancer and prevent relapses. 

Kainova focuses on breakthrough GPCR-modulating therapies in immuno-oncology and inflammation, built on decades of scientific and medical expertise from our leadership team, and our proprietary, validated approach. We foster a culture where scientific excellence and human purpose go hand in hand.

KisoJi is a privately-held next-generation antibody company developing multi-specific antibodies to improve outcomes in oncology. 

Neurasic Therapeutics is a company created to advance research that aims to provide new opiate-sparing pain-relieving drugs. 

Ocythera develops a compound that is unique, safe, and targets a specific enzyme for treatment of rare bone diseases.

Specific Biologics Inc.’s (SBI) mission is to develop novel gene editing technologies to treat diseases at the genetic level in cells inside the body. 

Flosonics Medical is a medical device company focused on developing non-invasive sensors to improve the management of critically-ill patients. 

Thryv Therapeutics Inc. is a precision medicine company developing novel SGK1 inhibitors for Long QT Syndrome and resistant cancers. With $15M in recent financing, the company is advancing proof-of-concept studies and preparing for IND submission. 

Zucara Therapeutics Inc. is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. 

Artelo Biosciences develops innovative therapeutics that modulate lipid-signaling pathways – an emerging approach with the potential to treat chronic conditions for which there are no or limited existing options, including pain, cancer, anxiety, and depression, amongst others. 

Bellus Health is developing BLU-5937, a P2X3 antagonist, to help people with chronic cough and other afferent hypersensitization-related disorders. 

Encycle Therapeutics was created to develop a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. 

Inversago Pharma is a clinical-stage, biotech company aiming to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. 

Kairos Therapeutics was a biopharmaceutical company that developed a proprietary next-generation antibody-drug conjugate platform.

Nexelis is an immunology-centric CRO specialized in preclinical models and clinical assay development in single and multiplex formats and sample analysis for low-, mid- and large-scale clinical testing.

Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. 

FORUS Therapeutics is a biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer.